JPWO2022255499A1 - - Google Patents

Info

Publication number
JPWO2022255499A1
JPWO2022255499A1 JP2023525939A JP2023525939A JPWO2022255499A1 JP WO2022255499 A1 JPWO2022255499 A1 JP WO2022255499A1 JP 2023525939 A JP2023525939 A JP 2023525939A JP 2023525939 A JP2023525939 A JP 2023525939A JP WO2022255499 A1 JPWO2022255499 A1 JP WO2022255499A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525939A
Other languages
Japanese (ja)
Other versions
JPWO2022255499A5 (cg-RX-API-DMAC7.html
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022255499A1 publication Critical patent/JPWO2022255499A1/ja
Publication of JPWO2022255499A5 publication Critical patent/JPWO2022255499A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023525939A 2021-06-04 2022-06-03 Pending JPWO2022255499A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021094481 2021-06-04
PCT/JP2022/023390 WO2022255499A1 (ja) 2021-06-04 2022-06-03 新規なamp活性化プロテインキナーゼ活性化剤

Publications (2)

Publication Number Publication Date
JPWO2022255499A1 true JPWO2022255499A1 (cg-RX-API-DMAC7.html) 2022-12-08
JPWO2022255499A5 JPWO2022255499A5 (cg-RX-API-DMAC7.html) 2025-06-09

Family

ID=84322602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525939A Pending JPWO2022255499A1 (cg-RX-API-DMAC7.html) 2021-06-04 2022-06-03

Country Status (5)

Country Link
US (1) US12622891B2 (cg-RX-API-DMAC7.html)
EP (1) EP4349331A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022255499A1 (cg-RX-API-DMAC7.html)
CN (1) CN117794527A (cg-RX-API-DMAC7.html)
WO (1) WO2022255499A1 (cg-RX-API-DMAC7.html)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043366A2 (en) 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
ES2328820T3 (es) 2003-10-17 2009-11-18 Astrazeneca Ab Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
CA2598458A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
JP2011178728A (ja) 2010-03-02 2011-09-15 Kobe Univ Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品
JP2013212994A (ja) * 2010-06-22 2013-10-17 Sanwa Kagaku Kenkyusho Co Ltd 新規チオフェンカルボキサミド誘導体及びその医薬用途
US20130345243A1 (en) 2011-03-07 2013-12-26 Glaxosmithkline Llc 1h-pyrollo[3,2-d]pyrimidinedione derivatives
WO2014069426A1 (ja) * 2012-10-31 2014-05-08 塩野義製薬株式会社 Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
CA2950119C (en) 2013-06-18 2021-09-14 Albert Einstein College Of Medicine, Inc. Treatment of obesity and pulmonary arterial hypertension
SG11201908817WA (en) 2017-03-21 2019-10-30 Fujifilm Corp Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound
JP7131034B2 (ja) 2018-03-30 2022-09-06 株式会社三洋物産 遊技機
JP7185226B2 (ja) * 2018-11-22 2022-12-07 国立大学法人 鹿児島大学 1,5-アンヒドロフルクトース誘導体を含むampk活性化剤
US11299582B2 (en) * 2019-04-29 2022-04-12 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Breathable elastomeric composites with tether-containing conducting polymers for nanoscale diffusion control and protection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, J. ET AL.: "AMPK activators: mechanisms of action and physiological activities", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 48, JPN6022030006, 2016, pages 224, ISSN: 0005908490 *
MICHAEL PILKINGTON-MIKSA ET AL.: ""Design, Synthesis, and Biological Evaluation of Novel cRGDPaclitaxel Conjugates for Integrin-Assis", BIOCONJUGATE CHEMISTRY, vol. 23, JPN6026029602, July 2012 (2012-07-01), pages 1610 - 1622, ISSN: 0005908489 *

Also Published As

Publication number Publication date
EP4349331A4 (en) 2025-06-11
WO2022255499A1 (ja) 2022-12-08
CN117794527A (zh) 2024-03-29
US12622891B2 (en) 2026-05-12
EP4349331A1 (en) 2024-04-10
US20240277657A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
BR122021002600B1 (pt) Mecanismo de articulação para equipamento agrícola, e equipamento agrícola
CN305970995S (zh) 杯盖(上尖款)
CN305921551S (zh) 云台(d-40)
CN305927849S (zh) 机动车轮毂(201017)
CN305922877S (zh) 机器人(喵喵)
CN305849708S (zh) 智能手环(h709)
CN305849456S (zh) 包装袋(贤哥每日营养蛋)
CN305878180S (zh) 路由器(570bv)
CN305843363S (zh) 电脑机箱面板(335c)
CN306049460S (zh) 钥匙包(虫妹妹)
CN305793907S (zh) 花洒(dt1901手柄)
CN305841117S (zh) 水杯(中宽口径大眼萌)
CN305796264S (zh) 食品加工机(wl202)
CN305796970S (zh) 名片盒
CN305789814S (zh) 电动骑行车(女款)
CN305929547S (zh) 三通连接件
CN305849015S (zh) 包装盒
CN305730503S (zh) 休闲椅(逍遥游)
CN305927505S (zh) 摆件(美萌鱼)
CN305842668S (zh) 电动自行车车架(g14)
CN305775238S (zh) 音频连接器(六角卡侬母头)
CN305844804S (zh) 儿童坐便圈
CN305731713S (zh) 茶盘(如日方中二)
CN305704248S (zh) 降噪扣
CN305850756S (zh) 汽车后保险杠总成

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250530

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250821

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260714